A Promising Breakthrough for Triple-Negative Breast Cancer by Targeting the AKT and EZH2

Zhuoyun Liu; Yirong Li; Xinghua Long

doi:10.1002/mco2.70318

MedComm ›› 2025, Vol. 6 ›› Issue (8) : e70318 DOI: 10.1002/mco2.70318

HIGHLIGHT

A Promising Breakthrough for Triple-Negative Breast Cancer by Targeting the AKT and EZH2

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhuoyun Liu, Yirong Li, Xinghua Long. A Promising Breakthrough for Triple-Negative Breast Cancer by Targeting the AKT and EZH2. MedComm, 2025, 6(8): e70318 DOI:10.1002/mco2.70318

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	A. E. Schade, N. Perurena, Y. Yang, et al., “AKT and EZH2 Inhibitors Kill TNBCs by Hijacking Mechanisms of Involution,” Nature 635, no. 8039 (2024): 755-763.

[2]

N. Turner, R. A. Dent, and J. O'Shaughnessy, “Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered Hormone Receptor-positive HER2-negative Advanced Breast Cancer: Primary Results From Cohort B of the IPATunity130 Randomized Phase 3 Trial,” Breast Cancer Research and Treatment 191, no. 3 (2022): 565-576.

[3]	K. L. Schwertfeger, J. L. McManaman, C. A. Palmer, M. C. Neville, and S. M. Anderson, “Expression of Constitutively Activated Akt in the Mammary Gland Leads to Excess Lipid Synthesis During Pregnancy and Lactation,” Journal of Lipid Research 44, no. 6 (2003): 1100-1112.

[4]	V. Malhi, N. Budha, R. Sane, et al., “Single- and Multiple-dose Pharmacokinetics, Potential for CYP3A Inhibition, and Food Effect in Patients With Cancer and Healthy Subjects Receiving ipatasertib,” Cancer Chemotheraphy and Pharmacology 88, no. 6 (2021): 921-930.

[5]	L. Xin, “EZH2 accompanies Prostate Cancer Progression,” Nature Cell Biology 23, no. 9 (2021): 934-936.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.